Agennix to restructure after trial failure

Agennix AG is set to restructure after the surprise failure of a Phase 3 trial of its lead product for non-small cell lung cancer, talactoferrin alfa (talactoferrin). The trial did not meet its primary endpoint of improving overall survival, despite promising earlier data.

Location